Close Menu
Invest Insider News
    Facebook X (Twitter) Instagram
    Saturday, November 21
    Facebook X (Twitter) Instagram Pinterest Vimeo
    Invest Insider News
    • Home
    • Bitcoin
    • Commodities
    • Finance
    • Investing
    • Property
    • Stock Market
    • Utilities
    Invest Insider News
    Home»Investing»AstraZeneca stock dips as HSBC downgrades stock on ’tough path ahead’ By Investing.com
    Investing

    AstraZeneca stock dips as HSBC downgrades stock on ’tough path ahead’ By Investing.com

    July 13, 20262 Mins Read


    Investing.com — HSBC has downgraded AstraZeneca () () to Hold from Buy and slashed its price target to 13,750 pence from 16,500 pence, after the drugmaker’s Wainua trial failed to meet its primary endpoint in a Phase 3 study.

    “Wainua setback impairs our bull case, given the more difficult catalyst path ahead,” HSBC analyst Rajesh Kumar said in a note.

    Shares in the British pharma giant fell 1.3% in London trading, while its U.S.-listed shares shed 1.5% in the premarket trade.

    Success in the CARDIO-TTR trial had underpinned HSBC’s positive view on the stock, Kumar noted, representing a market opportunity of more than $5 billion.

    The analyst cited three reasons for losing conviction in his bullish case. First, while the path to more than $80 billion in peak revenues by 2030 still exists, it now depends on catalysts that are more volatile and unlikely to read out before 2027.

    Second, HSBC’s own trial analysis left it “rather uncomfortable” with upcoming SERENA-4 and AVANZAR readouts expected in the second half of 2026.

    Finally, Kumar warned that “if three trials fail in a sequence, the widely held view of Astra’s market-leading R&D platform might lose its shine,” potentially capping the stock’s ability to re-rate.

    HSBC’s scenario analysis suggests that if the bear cases for SERENA-4 and AVANZAR play out, concerns about AstraZeneca’s ability to manage revenue decline amid large patent cliffs in the early 2030s would leave the company’s upside “capped on a 6-9-month basis,” reliant on catalyst successes in 2027.

    “We downgrade the stock to a Hold rating (from Buy) as we no longer find the risk-reward balance attractive, particularly with the remaining catalyst path for 2026 (SERENA‑4, AVANZAR) skewed to downside risks,” Kumar concluded.





    Source link

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
    Previous ArticleCommodities: Forward curves and carry framework – Societe Generale
    Next Article Can this chip sector work if memory doesn’t? By Investing.com

    Related Posts

    Investing

    NZD/INR Historical Data | New Zealand Dollar Indian Rupee

    October 30, 2026
    Investing

    GBP 2 Years IRS Interest Rate Swap Bond Chart (Live Data)

    October 27, 2026
    Investing

    USD/CNY Historical Data | US Dollar Chinese Yuan

    October 25, 2026
    Leave A Reply Cancel Reply

    Top Posts

    How is the UK Commercial Property Market Performing?

    December 31, 2000

    How much are they in different states across the US?

    December 31, 2000

    A Guide To Becoming A Property Developer

    December 31, 2000
    Stay In Touch
    • Facebook
    • YouTube
    • TikTok
    • WhatsApp
    • Twitter
    • Instagram
    Latest Reviews
    Bitcoin

    Bitcoin’s Five-Day Surge to $77K: What Cost-Basis Levels Reveal

    August 23, 2026
    Property

    UK estate agents’ optimism on home sales hits highest level in over a year

    January 14, 2026
    Bitcoin

    Bitcoin faces tech selloff risk as funds cut exposure

    November 19, 2026
    What's Hot

    The Impact of War on the Stock Markets—What Investors Need To Know

    March 3, 2026

    Half of UK homes listed never sell — how can sellers change the odds?

    May 13, 2026

    Benefits, Revenue Generation, and Management

    February 15, 2023
    Most Popular

    Kairos Pharma présente ses réalisations de 2024 et ses objectifs pour 2025 Par Investing.com

    January 21, 2025

    ‘Tipp-Ex divorcee’ is locked in High Court libel fight with property developer over his plans for housing in grounds of her £6.75m castle

    July 24, 2025

    Ganglong China Property enregistre 1,80 milliard de yuans de ventes contractuelles entre janvier et avril

    May 14, 2025
    Editor's Picks

    Vivendi plans to list Canal+ on the London Stock Exchange.

    July 22, 2024

    LSL Property Services prévoit une nouvelle croissance de ses bénéfices en 2025

    May 27, 2025

    Il lance une académie Bitcoin révolutionnaire

    March 26, 2025
    Facebook X (Twitter) Instagram Pinterest Vimeo
    • Get In Touch
    • Privacy Policy
    • Terms and Conditions
    © 2026 Invest Insider News

    Type above and press Enter to search. Press Esc to cancel.